ArticleIn vivo (Athens, Greece)

Comparison of the Use of Immune Checkpoint Inhibitor/Tyrosine Kinase Inhibitor and Tyrosine Kinase Inhibitor Alone for Patients With Low Risk Metastatic Renal Cell Carcinoma.

Masaharu Oki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.